このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aeterna Zentaris マネジメント

マネジメント基準チェック /44

Aeterna Zentaris'の CEO はGilles Gagnonで、 Jun2024年に任命され、の在任期間は 4.42年です。は、会社の株式の4.71%を直接所有しており、その価値は$ 163.46K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と8.1年です。

主要情報

Gilles Gagnon

最高経営責任者

US$133.5k

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	4.7%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Feb 02

CEO（最高経営責任者

Gilles Gagnon (70 yo)

no data

在職期間

US$133,500

報酬

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Director of Aeterna Zentaris Inc. since June 03, 2024 and had been its Independent Director since January 1, 2020 until June 2024 and serves its as Preside...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gilles Gagnon	President	no data	US$133.50k	4.71% $ 158.8k
Giuliano La Fratta	Senior VP of Finance & CFO	2.4yrs	US$254.19k	データなし
Michael Teifel	Senior VP of Non-Clinical Development & Chief Scientific Officer	3.1yrs	US$248.24k	データなし
Nicola Ammer	Chief Medical Officer & Senior VP of Clinical Development	6.4yrs	US$212.55k	データなし
Matthias Gerlach	Senior Vice President Manufacturing and Supply Chain & Head of Production	no data	US$263.11k	データなし

2.8yrs

平均在職期間

経験豊富な経営陣: AEZSの経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gilles Gagnon	President	4.4yrs	US$133.50k	4.71% $ 158.8k
Dennis Turpin	Independent Director	3.1yrs	US$229.00k	0.042% $ 1.4k
Genevieve Foster	Independent Director	no data	データなし	データなし
Gerald Batist	Member of the Scientific Advisory Board	no data	データなし	データなし
Hartmut Michel	Member of the Scientific Advisory Board	no data	データなし	データなし
Ronald Miller	Independent Chairman	no data	データなし	データなし
Marcel Verheij	Member of the Scientific Advisory Board	no data	データなし	データなし
René Frydman	Member of the Scientific Advisory Board	no data	データなし	データなし
Alan DeCherney	Member of the Scientific Advisory Board	no data	データなし	データなし
Klaus Diedrich	Member of the Scientific Advisory Board	no data	データなし	データなし
Frans Debruyne	Member of the Scientific Advisory Board	no data	データなし	データなし
Carolyn Egbert	Independent Director	11.8yrs	US$244.00k	0.042% $ 1.4k

3.8yrs

平均在職期間

経験豊富なボード: AEZSの取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

Aeterna Zentaris マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

Recent updates

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna slips ~10% after announcing date of reverse stock split

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$1.50

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Aeterna Zentaris names Michael Teifel as chief scientific officer

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: US$1.08

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: US$0.69

New 90-day high: US$0.51

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

New 90-day high: US$0.44

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: US$0.33

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low: US$0.38

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /44